ISSN: ISSN 2472-0429

Fortschritte in der Krebsprävention

Offener Zugang

Unsere Gruppe organisiert über 3000 globale Konferenzreihen Jährliche Veranstaltungen in den USA, Europa und anderen Ländern. Asien mit Unterstützung von 1000 weiteren wissenschaftlichen Gesellschaften und veröffentlicht über 700 Open Access Zeitschriften, die über 50.000 bedeutende Persönlichkeiten und renommierte Wissenschaftler als Redaktionsmitglieder enthalten.

Open-Access-Zeitschriften gewinnen mehr Leser und Zitierungen
700 Zeitschriften und 15.000.000 Leser Jede Zeitschrift erhält mehr als 25.000 Leser

Abstrakt

Stroma-derived extracellular vesicles deliver tumor-suppressive mi-RNAs to pancreatic cancer cells

Song Han

The biology of tumor-associated stroma (TAS) in pancreatic ductal adenocarcinoma (PDAC) is not well understood.
The paradoxical observation that stroma-depletion strategies lead to progression of PDAC reinforced the need to
critically evaluate the functional contribution of TAS in the initiation and progression of PDAC. PDAC and TAS cells
are unique in their expression of specific miRNAs, and this specific miRNA expression pattern alters host to tumor
microenvironment interactions. Using primary human pancreatic TAS cells and primary xenograft PDAC cells coculture,
we provided evidence of miRNA trafficking and exchanging between TAS and PDAC cells, in a two-way,
cell-contact independent fashion, via extracellular vesicles (EVs) transportation. Selective packaging of miRNAs into
EVs led to enrichment of stromal specific miR-145 in EVs secreted by TAS cells. Highly-concentrated exosomes,
but not micro-vesicles, derived from human TAS cells demonstrated a tumor suppressive role by inducing PDAC cell
apoptosis. This effect was mitigated by anti-miR-145 sequences. Our data suggest that TAS-derived miRNAs are
delivered to adjacent PDAC cells via exosomes and suppress tumor cell growth. These data highlight that TAS cells
secrete exosomes carrying tumor suppressive genetic materials, a possible anti-tumor capacity. Future work of the
development of patient-derived exosomes could have therapeutic implications for unresectable PDAC